A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) (NCT06698042)
A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS 50% or Greater
🩺 Plain-English Summary (8th-Grade Level)
Researchers are looking for new ways to treat non-small cell lung cancer (NSCLC) that is metastatic, which means cancer has spread to other parts of the body. Some people with metastatic NSCLC are treated with pembrolizumab, an immunotherapy treatment that is given into a vein as an intravenous (IV) infusion. Pembrolizumab (+) Berahyaluronidase alfa is pembrolizumab that is given under the skin as a subcutaneous (SC) injection. The goal of this study is to learn what happens to pembrolizumab in a person's body over time when it is given as an IV infusion or SC injection.
Who can join: Review the eligibility criteria below.
Location: Providence Medical Foundation ( Site 0117) — Fullerton, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (67 Sites)
Showing the first 25 of 67 sites.
- Providence Medical Foundation ( Site 0117) — Fullerton, California
- Illinois Cancer Care ( Site 0101) — Peoria, Illinois
- Montefiore Medical Center ( Site 0104) — The Bronx, New York
- University of Cincinnati Medical Center ( Site 0112) — Cincinnati, Ohio
- Beijing Peking Union Medical College Hospital ( Site 5000) — Beijing, Beijing Municipality
- Chongqing University Three Gorges Hospital ( Site 5018) — Chongqing, Chongqing Municipality
- Fujian Province Cancer Hospital ( Site 5007) — Fuzhou, Fujian
- The First Affiliated hospital of Xiamen University ( Site 5008) — Xiamen, Fujian
- The first affiliated hospital, Sun Yat-Sen university ( Site 5011) — Guangzhou, Guangdong
- Southern Medical University Nanfang Hospital ( Site 5003) — Guangzhou, Guangdong
- Huizhou Central People's Hospital ( Site 5004) — Huizhou, Guangdong
- Jiangmen Center Hospital ( Site 5001) — Jiangmen, Guangdong
- Liuzhou People's Hospital ( Site 5009) — Liuzhou, Guangxi
- Wuhan Union Hospital Cancer Center-Cancer Center ( Site 5015) — Wuhan, Hubei
- The First Affiliated Hospital of Nanchang University ( Site 5019) — Nanchang, Jiangxi
- Jilin Province Tumor Hospital ( Site 5014) — Changchun, Jilin
- Jinan Central Hospital ( Site 5012) — Jinan, Shandong
- Shanghai Pulmonary Hospital ( Site 5010) — Shanghai, Shanghai Municipality
- West China Hospital of Sichuan University ( Site 5016) — Chengdu, Sichuan
- Sichuan Cancer Hospital. ( Site 5006) — Chengdu, Sichuan
- Sir Run Run Shaw Hospital of Zhejiang University School of Medicine ( Site 5021) — Hangzhou, Zhejiang
- Taizhou Hospital of Zhejiang Province ( Site 5002) — Linhai, Zhejiang
- HELIOS Klinikum Erfurt ( Site 2005) — Erfurt, Thuringia
- Universitätsklinikum Jena ( Site 2002) — Jena, Thuringia
- MEDI-K ( Site 1101) — Guatemala City,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lung Cancer
- Implementation Strategies for Monitoring Adherence in Real Time — Philadelphia, Pennsylvania
- Early Detection of Lung Cancer — Nashville, Tennessee
- Improving Utilization of Lung Cancer Screening in Underserved PA Populations — Allentown, Pennsylvania
- Effect of Pulmonary Rehabilitation on Surgical Outcomes in the Cancer Setting — Houston, Texas
- Testing the Engaged Approach to Lung Cancer Screening — Denver, Colorado
- Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer — Boston, Massachusetts
Explore by condition: All Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.